Respiratory imaging technology specialist 4DMedical (ASX: 4DX) has won a contract with the US Department of Defense (DoD) to pilot its CT Ventilation-Perfusion (CT:VQ) technology to assess lung health in a fixed cohort of active duty personnel.
This contract builds on the success of 4DMedical's earlier agreement with the DoD for the deployment of its CT Lung Ventilation Analysis Software (CT LVASTM) in a clinical pilot program. The new arrangement reflects the DoD's recognition of the utility and impact of 4DMedical's technology in delivering critical health insights for active military personnel.
The contracted arrangement with the DoD is best characterised as a commercial pilot, involving the delivery of a fixed number of scan analysis reports on full commercial terms.
The DoD operates one of the largest and most comprehensive healthcare systems in the world, serving over 9.6 million active-duty service members, their families, and retirees across the Military Health System (MHS). With over 200 military hospitals and clinics globally, the MHS is tasked with providing high-quality, integrated healthcare to ensure the readiness and resilience of the US Armed Forces.
Under the agreement, 4DMedical will leverage its CT:VQ platform to conduct assessments of lung health, on 80 active-duty personnel within the DoD. This innovative imaging solution will provide unparalleled insights into ventilation and perfusion abnormalities, assisting in the early detection and monitoring of a wide range of pulmonary conditions including COPD and chronic thromboembolic hypertension. The technology is also relevant for personnel exposed to hazardous environments during military service and potentially living with associated deployment-related lung diseases.
4DMedical’s CT:VQ technology represents a game-changing innovation in lung imaging, offering a non- invasive, highly detailed view of both ventilation and perfusion within the lungs.
This advanced imaging solution offers a compelling alternative to traditional Nuclear VQ scans, providing clinicians with comparable diagnostic insights while eliminating the need for radioactive isotopes and other expensive infrastructure requirements. This capability, when released, will enable clinicians to make more precise diagnoses, thereby improving patient outcomes, increasing access to care and reducing healthcare costs.
The evaluation of CT:VQTM with the DoD, prior to FDA clearance, reaffirms the intense interest in this game- changing technology from clinicians across the U.S., while also providing a strong foundation for further opportunities within the DoD and the VA.
“We are honoured to receive continued interest in the use of our technology from the DoD as a new pathway to enhance lung health outcomes for military personnel, 4DMedical MD/CEO and Founder, Andreas Fouras, said.
“This new contract underscores the value of 4DMedical's imaging solutions in addressing the unique health challenges faced by service members. We look forward to working closely with the DoD to deliver actionable insights that contribute to the readiness and well-being of the U.S. Armed Forces.”
